<DOC>
	<DOCNO>NCT01455259</DOCNO>
	<brief_summary>In phase I/II trial , immunostimulatory gene therapy ( AdCD40L ) investigate . In Part 1 patient melanoma receive AdCD40L mono therapy . In Part 2A , patient melanoma patient solid tumor receive AdCD40L combination low dose cyclophosphamide . In Part 2B , patient melanoma receive AdCD40L combination one local radiotherapy cyclophosphamide .</brief_summary>
	<brief_title>Phase I/IIa AdCD40L Immunogene Therapy Malignant Melanoma Other Solid Tumors</brief_title>
	<detailed_description>In phase I/II trial , immunostimulatory gene therapy ( AdCD40L ) investigate . In Part 1 patient melanoma ( n=6 ) receive AdCD40L mono therapy . In Part 2A , patient melanoma ( n=9 ) patient solid tumor ( n=6 ) receive AdCD40L combination low dose cyclophosphamide . In Part 2B , patient melanoma receive AdCD40L combination one local radiotherapy cyclophosphamide . AdCD40L give weekly injection 2.5x10e11 VP , 4x ; total dose 1x10e12 VP . A maximum 30 patient include trial . AdCD40L adenoviral nonreplicating vector carry human CD40L gene . AdCD40L infect tumor cell upon intratumoral injection deliver CD40L gene cell whereupon virus destroy . CD40L express membrane-bound protein interacts CD40 receptor express example dendritic cell ( DCs ) tumor area . DCs mature upon CD40/CD40L interaction activate tumor-specific T cell response .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically proven diagnosis malignant solid cancer , ECOG 02 . Disease progression establish treatment patient eligible standard option . Signed informed consent must obtain . Pregnancy . Life expectancy le 3 month . Any significant medical psychiatric illness would prevent patient give informed consent follow study procedure . Patients severe systemic autoimmune disease . Patients consent tissue blood sample store biobank .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AdCD40L</keyword>
	<keyword>Adenoviral vector</keyword>
	<keyword>CD40L</keyword>
	<keyword>CD154</keyword>
	<keyword>malignant melanoma</keyword>
</DOC>